Breast malignancy often leads to skin dimpling and nipple retraction, which are caused by the tumour infiltrating the breast ligaments and ducts. The axillary contents are enclosed by the clavipectoral fascia, and the breast’s lymphatic drainage occurs in both the axilla and internal mammary chain. The breast is highly vascularized, with the internal mammary artery being a subclavian artery branch.

The breast is situated on a layer of pectoral fascia and is surrounded by the pectoralis major, serratus anterior, and external oblique muscles. The nerve supply to the breast comes from branches of intercostal nerves from T4-T6, while the arterial supply comes from the internal mammary (thoracic) artery, external mammary artery (laterally), anterior intercostal arteries, and thoraco-acromial artery. The breast’s venous drainage is through a superficial venous plexus to subclavian, axillary, and intercostal veins. Lymphatic drainage occurs through the axillary nodes, internal mammary chain, and other lymphatic sites such as deep cervical and supraclavicular fossa (later in disease).

The preparation for lactation involves the hormones oestrogen, progesterone, and human placental lactogen. Oestrogen promotes duct development in high concentrations, while high levels of progesterone stimulate the formation of lobules. Human placental lactogen prepares the mammary glands for lactation. The two hormones involved in stimulating lactation are prolactin and oxytocin. Prolactin causes milk secretion, while oxytocin causes contraction of the myoepithelial cells surrounding the mammary alveoli to result in milk ejection from the breast. Suckling of the baby stimulates the mechanoreceptors in the nipple, resulting in the release of both prolactin and oxytocin from the pituitary gland (anterior and posterior parts respectively).

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

Pregnancy can be detected through urine tests that identify the beta subunit of the human chorionic gonadotrophin. This hormone increases during the first trimester of pregnancy to support progesterone production by the corpus luteum. Although the alpha subunit of this hormone is identical to that of other hormones, such as luteinising hormone, follicle stimulating hormone, and thyroid stimulating hormone, it is the beta subunit that is recognized and used as a marker for pregnancy. The pituitary gland secretes luteinising hormone and follicle stimulating hormone in all humans, but these hormones are not indicative of pregnancy.

Understanding Ectopic Pregnancy: The Pathophysiology

Ectopic pregnancy occurs when the fertilized egg implants outside the uterus, most commonly in the fallopian tube. In fact, 97% of ectopic pregnancies occur in the tubal region, with the majority in the ampulla. However, if the implantation occurs in the isthmus, it can be more dangerous. The remaining 3% of ectopic pregnancies can occur in the ovary, cervix, or peritoneum.

During ectopic pregnancy, the trophoblast, which is the outer layer of cells that forms the placenta, invades the tubal wall. This invasion can cause bleeding, which may dislodge the embryo. The natural history of ectopic pregnancy includes absorption and tubal abortion, with the latter being the most common. In tubal abortion, the embryo is expelled from the tube, resulting in bleeding and pain. In tubal absorption, the tube may not rupture, and the blood and embryo may be shed or converted into a tubal mole and absorbed. However, if the tube ruptures, it can lead to severe bleeding and potentially life-threatening complications.

In summary, understanding the pathophysiology of ectopic pregnancy is crucial in identifying and managing this potentially life-threatening condition. Early diagnosis and prompt treatment can help prevent complications and improve outcomes for affected individuals.

The most frequent breast lumps in women aged 15-25 are fibroadenomas. These lumps are usually firm, mobile, and less than 3 cm in size. They are not a cause for concern and typically disappear within a few years.

Fat necrosis is a condition that occurs after breast trauma, such as a sports injury or core needle biopsy. The affected area may be tender and show bruising. However, it usually resolves on its own and is unlikely to persist for an extended period.

Overview of Benign Breast Lesions

Benign breast lesions are non-cancerous growths that can occur in the breast tissue. There are several types of benign breast lesions, each with their own unique features and treatment options.

Fibroadenomas are one of the most common types of benign breast lesions, accounting for 12% of all breast masses. They develop from a whole lobule and are typically mobile, firm breast lumps. While they do not increase the risk of malignancy, surgical excision is usually recommended if the lesion is larger than 3 cm. Phyllodes tumors, a rare type of fibroadenoma, should be widely excised or removed with a mastectomy if the lesion is large.

Breast cysts are another common type of benign breast lesion, with 7% of all Western females presenting with one. They usually present as a smooth, discrete lump and may be aspirated. However, if the cyst is blood-stained or persistently refills, it should be biopsied or excised.

Sclerosing adenosis, radial scars, and complex sclerosing lesions can cause mammographic changes that mimic carcinoma. However, they are considered a disorder of involution and do not increase the risk of malignancy. Biopsy is recommended, but excision is not mandatory.

Epithelial hyperplasia is a disorder that consists of increased cellularity of the terminal lobular unit, and atypical features may be present. Those with atypical features and a family history of breast cancer have a greatly increased risk of malignancy and may require surgical resection.

Fat necrosis can occur in up to 40% of cases and usually has a traumatic cause. Physical features may mimic carcinoma, but imaging and core biopsy can help diagnose the lesion.

Duct papillomas usually present with nipple discharge and may require microdochectomy if they are large. However, they do not increase the risk of malignancy.

Overall, benign breast lesions can have varying presentations and treatment options. It is important to consult with a healthcare provider to determine the best course of action for each individual case.

During pregnancy, plasma urea and creatinine levels decrease due to increased renal perfusion, which allows for more efficient clearing of these substances from the circulation. Additionally, the increased plasma volume dilutes these substances. This is a result of physiological changes in pregnancy, such as increased uterine size, cervical ectropion, and increased vaginal discharge. Cardiovascular and haemodynamic changes also occur, including increased plasma volume and decreased levels of albumin, urea, and creatinine. Progesterone-related effects, such as muscle relaxation, can lead to decreased blood pressure, constipation, and bladder relaxation. It is important to note that the foetus does not have functioning kidneys, and the mother filters the blood for it.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

The process of preparing for lactation involves the hormones oestrogen, progesterone, and human placental lactogen. Oestrogen promotes the development of ducts, while high levels of progesterone stimulate the formation of lobules. Human placental lactogen prepares the mammary glands for lactation.

The two hormones responsible for stimulating lactation are prolactin and oxytocin. Prolactin stimulates milk production, while oxytocin causes the contraction of myoepithelial cells surrounding the mammary alveoli, resulting in milk ejection from the breast.

When the baby suckles, the mechanoreceptors in the nipple are stimulated, leading to the release of both prolactin and oxytocin from the anterior and posterior parts of the pituitary gland, respectively.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

When the baby has Rh-positive blood and the mother has Rh-negative blood, their blood supplies can mix during pregnancy. This can lead to the mother producing antibodies that may harm the baby by passing through the placenta and causing conditions like hydrops fetalis. Additionally, subsequent pregnancies may also be impacted.

Rhesus negative mothers can develop anti-D IgG antibodies if they deliver a Rh +ve child, which can cause haemolysis in future pregnancies. Prevention involves testing for D antibodies and giving anti-D prophylaxis at 28 and 34 weeks. Anti-D should also be given in various situations, such as delivery of a Rh +ve infant or amniocentesis. Tests include cord blood FBC, blood group, direct Coombs test, and Kleihauer test. Affected fetuses may experience oedema, jaundice, anaemia, hepatosplenomegaly, heart failure, and kernicterus, and may require transfusions and UV phototherapy.

Pelvic inflammatory disease is most commonly caused by chlamydia and gonorrhoeae, with gonorrhoeae being the likely cause in this patient since they do not have chlamydia. While HIV does not directly cause pelvic inflammatory disease, it can increase the risk of contracting sexually transmitted infections. Syphilis follows its own distinct clinical course and does not cause pelvic inflammatory disease, while herpes typically presents with painful genital blisters but does not cause pelvic inflammatory disease.

Pelvic inflammatory disease (PID) is a condition where the female pelvic organs, including the uterus, fallopian tubes, ovaries, and surrounding peritoneum, become infected and inflamed. It is typically caused by an infection that spreads from the endocervix. The most common causative organism is Chlamydia trachomatis, followed by Neisseria gonorrhoeae, Mycoplasma genitalium, and Mycoplasma hominis. Symptoms of PID include lower abdominal pain, fever, dyspareunia, dysuria, menstrual irregularities, vaginal or cervical discharge, and cervical excitation.

To diagnose PID, a pregnancy test should be done to rule out an ectopic pregnancy, and a high vaginal swab should be taken to screen for Chlamydia and gonorrhoeae. However, these tests may often be negative, so consensus guidelines recommend having a low threshold for treatment due to the potential complications of untreated PID. Management typically involves oral ofloxacin and oral metronidazole or intramuscular ceftriaxone, oral doxycycline, and oral metronidazole. In mild cases of PID, intrauterine contraceptive devices may be left in, but the evidence is limited, and removal of the IUD may be associated with better short-term clinical outcomes according to recent guidelines.

Complications of PID include perihepatitis (Fitz-Hugh Curtis Syndrome), which occurs in around 10% of cases and is characterized by right upper quadrant pain that may be confused with cholecystitis, infertility (with a risk as high as 10-20% after a single episode), chronic pelvic pain, and ectopic pregnancy.

Anastrozole and letrozole are medications that inhibit the production of oestrogen in peripheral tissues through the enzyme aromatase. These drugs are commonly used to treat breast cancer in postmenopausal women.

Trastuzumab is a monoclonal antibody that targets HER2 receptors on cancer cells, inhibiting their growth and proliferation. It is effective in treating HER2-positive breast cancer.

Fulvestrant is a selective oestrogen receptor degrader that breaks down oestrogen receptors without activating them, unlike tamoxifen. This leads to downregulation of the receptor.

Goserelin is an LHRH agonist that suppresses oestrogen production by the ovaries. It is often used as adjuvant therapy in premenopausal women.

Tamoxifen is an antagonist (and partial agonist) of the oestrogen receptor. It is particularly useful in treating oestrogen-receptor positive breast cancer, especially in patients who have not yet gone through menopause.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen may cause adverse effects such as menstrual disturbance, hot flushes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors may cause adverse effects such as osteoporosis, hot flushes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

Understanding Ovarian Cancer: Risk Factors, Symptoms, and Management

Ovarian cancer is a type of cancer that affects women, with the peak age of incidence being 60 years. It is the fifth most common malignancy in females and carries a poor prognosis due to late diagnosis. Around 90% of ovarian cancers are epithelial in origin, with 70-80% of cases being due to serous carcinomas. Interestingly, recent studies suggest that the distal end of the fallopian tube is often the site of origin of many ‘ovarian’ cancers.

There are several risk factors associated with ovarian cancer, including a family history of mutations of the BRCA1 or the BRCA2 gene, early menarche, late menopause, and nulliparity. Clinical features of ovarian cancer are notoriously vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms, early satiety, and diarrhea.

To diagnose ovarian cancer, a CA125 test is usually done initially. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 should not be used for screening for ovarian cancer in asymptomatic women. Diagnosis is difficult and usually involves diagnostic laparotomy.

Management of ovarian cancer usually involves a combination of surgery and platinum-based chemotherapy. The prognosis for ovarian cancer is poor, with 80% of women having advanced disease at presentation and the all stage 5-year survival being 46%. It is traditionally taught that infertility treatment increases the risk of ovarian cancer, as it increases the number of ovulations. However, recent evidence suggests that there is not a significant link. The combined oral contraceptive pill reduces the risk (fewer ovulations) as does having many pregnancies.

The correct diagnosis for this patient is endometriosis, as she exhibits the typical symptoms of vague pelvic pain, deep dyspareunia, and pain during defecation. These symptoms are caused by the presence of extra-pelvic endometrial tissue that bleeds and irritates the bowel or recto-vaginal pouch.

Adenomyosis, on the other hand, typically presents with dysmenorrhoea, dyspareunia, and menorrhagia, which are not present in this patient.

Pelvic inflammatory disease may cause pelvic pain and deep dyspareunia, but it is usually chronic and not cyclical like the pain experienced by this patient. Pain during defecation is also not a common symptom.

Fibroids may cause pelvic pain, but they do not typically cause dyspareunia or pain during defecation. Menorrhagia is a common symptom of fibroids.

Endometriosis is a condition where endometrial tissue grows outside of the uterus, affecting around 10% of women of reproductive age. Symptoms include chronic pelvic pain, painful periods, pain during sex, and subfertility. Diagnosis is made through laparoscopy, and treatment depends on the severity of symptoms. First-line treatments include NSAIDs and hormonal treatments such as the combined oral contraceptive pill or progestogens. If these do not improve symptoms or fertility is a priority, referral to secondary care may be necessary. Treatment options in secondary care include GnRH analogues and surgery, with laparoscopic excision or ablation of endometriosis plus adhesiolysis recommended for women trying to conceive. Ovarian cystectomy may also be necessary for endometriomas.

The Onufs nucleus, which is responsible for providing neurons to the external urethral sphincter, is located in the anterior horn of S2. In females, the sphincter complex at the bladder neck is not well-developed, making the external sphincter complex more important. It is innervated by the pudendal nerve, and damage to this nerve due to obstetric events can lead to stress urinary incontinence. The bladder is innervated by the pudendal, hypogastric, and pelvic nerves, which also carry autonomic nerves. Sympathetic nerves cause detrusor relaxation and sphincter contraction during bladder filling, while parasympathetic nerves cause detrusor contraction and sphincter relaxation. The Pons is responsible for centrally mediating control of micturition.

Urinary incontinence is a common condition that affects approximately 4-5% of the population, with elderly females being more susceptible. There are several risk factors that can contribute to the development of urinary incontinence, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. The condition can be classified into different types, such as overactive bladder, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of urinary incontinence involves completing bladder diaries for at least three days, performing a vaginal examination to exclude pelvic organ prolapse, and conducting urine dipstick and culture tests. Urodynamic studies may also be necessary. Management of urinary incontinence depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures may be necessary. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be offered to women who decline surgical procedures.

In summary, urinary incontinence is a common condition that can be caused by various risk factors. It can be classified into different types, and management depends on the predominant type of incontinence. Initial investigation involves completing bladder diaries, performing a vaginal examination, and conducting urine tests. Treatment options include bladder retraining, bladder stabilizing drugs, pelvic floor muscle training, surgical procedures, and duloxetine.

Androgens play a crucial role in the development of male reproductive organs, as they stimulate the formation of Wolffian ducts that eventually give rise to the vas deferens, epididymis, and seminal vesicles. In the absence of androgen activity, the Wolffian ducts break down, leading to the failure of male reproductive organ development. Additionally, Sertoli cells produce anti-Mullerian hormone, which prevents the formation of female internal genitalia. The lack of androgen effects also results in the absence of masculine characteristics in the external genitalia.

Understanding Androgen Insensitivity Syndrome

Androgen insensitivity syndrome is a genetic condition that affects individuals with an XY genotype, causing them to develop a female phenotype due to their body’s resistance to testosterone. This condition was previously known as testicular feminization syndrome. Common features of this condition include primary amenorrhea, little to no pubic and axillary hair, undescended testes leading to groin swellings, and breast development due to the conversion of testosterone to estrogen.

Diagnosis of androgen insensitivity syndrome can be done through a buccal smear or chromosomal analysis, which reveals a 46XY genotype. After puberty, testosterone levels in individuals with this condition are typically in the high-normal to slightly elevated range for postpubertal boys.

Management of androgen insensitivity syndrome involves counseling and raising the child as female. Bilateral orchidectomy is recommended to reduce the risk of testicular cancer due to undescended testes. Additionally, estrogen therapy may be used to promote the development of secondary sexual characteristics. Understanding androgen insensitivity syndrome is crucial for proper diagnosis and management of affected individuals.

First-line treatment for urinary incontinence is bladder retraining for urge incontinence and pelvic floor muscle training for stress incontinence. Surgery is a later option. Toileting aids and decreasing fluid intake should not be advised. Patients should drink 6-8 glasses of water per day.

Urinary incontinence is a common condition that affects approximately 4-5% of the population, with elderly females being more susceptible. There are several risk factors that can contribute to the development of urinary incontinence, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. The condition can be classified into different types, such as overactive bladder, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of urinary incontinence involves completing bladder diaries for at least three days, performing a vaginal examination to exclude pelvic organ prolapse, and conducting urine dipstick and culture tests. Urodynamic studies may also be necessary. Management of urinary incontinence depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures may be necessary. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be offered to women who decline surgical procedures.

In summary, urinary incontinence is a common condition that can be caused by various risk factors. It can be classified into different types, and management depends on the predominant type of incontinence. Initial investigation involves completing bladder diaries, performing a vaginal examination, and conducting urine tests. Treatment options include bladder retraining, bladder stabilizing drugs, pelvic floor muscle training, surgical procedures, and duloxetine.

Breast Milk lactoferrin facilitates the quick absorption of iron in the gut, while simultaneously limiting the amount of iron accessible to gut bacteria due to its antibacterial properties. Additionally, lactoferrin has been found to promote bone health by increasing bone formation and reducing bone resorption.

Advantages and Disadvantages of Breastfeeding

Breastfeeding has numerous advantages for both the mother and the baby. For the mother, it promotes bonding with the baby and helps with the involution of the uterus. It also provides protection against breast and ovarian cancer and is a cheap alternative to formula feeding as there is no need to sterilize bottles. However, it should not be relied upon as a contraceptive method as it is unreliable.

Breast milk contains immunological components such as IgA, lysozyme, and lactoferrin that protect mucosal surfaces, have bacteriolytic properties, and ensure rapid absorption of iron so it is not available to bacteria. This reduces the incidence of ear, chest, and gastrointestinal infections, as well as eczema, asthma, and type 1 diabetes mellitus. Breastfeeding also reduces the incidence of sudden infant death syndrome.

One of the advantages of breastfeeding is that the baby is in control of how much milk it takes. However, there are also disadvantages such as the transmission of drugs and infections such as HIV. Prolonged breastfeeding may also lead to nutrient inadequacies such as vitamin D and vitamin K deficiencies, as well as breast milk jaundice.

In conclusion, while breastfeeding has numerous advantages, it is important to be aware of the potential disadvantages and to consult with a healthcare professional to ensure that both the mother and the baby are receiving adequate nutrition and care.

During pregnancy, it is common to experience pubic symphysis dysfunction due to increased ligament laxity caused by hormonal changes. This can result in pain over the pubic symphysis that may radiate to the groins and inner thighs. It is important to differentiate this from more serious conditions such as cauda equina syndrome, which is a surgical emergency and presents with low back pain, leg pain, numbness around the anus, and loss of bowel or bladder control. While slipped lumbar vertebrae can also cause similar symptoms, it is less common than pubic symphysis dysfunction during pregnancy. Ultrasound scans can confirm a normal fetus, ruling out ectopic pregnancy and miscarriage as potential causes of the symptoms.

Understanding Symphysis Pubis Dysfunction in Pregnancy

Symphysis pubis dysfunction (SPD), also known as pelvic girdle pain, is a common condition experienced by pregnant women. It is caused by the hormone relaxin, which affects the laxity of ligaments in the pelvic girdle and other parts of the body. This increased laxity can result in pain and instability in the symphysis pubis joint and/or sacroiliac joint. Around 20% of women suffer from SPD by 33 weeks of gestation, and it can occur at any time during pregnancy or in the postnatal period.

Multiple risk factors have been identified, including a previous history of low back pain, multiparity, previous trauma to the back or pelvis, heavy workload, higher levels of stress, and job dissatisfaction. Patients typically present with discomfort and pain in the suprapubic or low back area, which may radiate to the upper thighs and perineum. Pain can range from mild to severe and is often exacerbated by walking, climbing stairs, turning in bed, standing on one leg, or weight-bearing activities.

Physical examination may reveal tenderness of the symphysis pubis and/or sacroiliac joint, pain on hip abduction, pain at the symphysis when standing on one leg, and a waddling gait. Positive Faber and active straight leg raise tests, as well as palpation of the anterior surface of the symphysis pubis, can also indicate SPD. Imaging, such as ultrasound or MRI, is necessary to confirm separation of the symphysis pubis.

Conservative management with physiotherapy is the primary treatment for SPD. Understanding the risk factors and symptoms of SPD can help healthcare providers provide appropriate care and support for pregnant women experiencing this condition.

Pelvic inflammatory disease can be a challenging diagnosis for emergency practitioners, as it presents with vague abdominal pain that can be mistaken for a surgical or gynecological issue. While CT scans are not ideal for young patients due to the risk of radiation exposure to the sex organs, they can reveal common findings for pelvic inflammatory disease, such as free fluid in the pouch of Douglas, pelvic fat stranding, tubo-ovarian abscesses, and fallopian tube thickening of more than 5 mm. In contrast, CT scans for appendicitis may show appendiceal dilatation, thickening of the caecal apex with a bar sign, periappendiceal fat stranding and phlegmon, and focal wall nonenhancement in cases of gangrenous appendix. The most common cause of pelvic inflammatory disease is Chlamydia trachomatis, followed by Neisseria gonorrhoeae and Mycobacterium tuberculosis. In cases of appendicitis, Escherichia coli is the most likely causative organism, with rare cases caused by other organisms.

Pelvic inflammatory disease (PID) is a condition where the female pelvic organs, including the uterus, fallopian tubes, ovaries, and surrounding peritoneum, become infected and inflamed. It is typically caused by an infection that spreads from the endocervix. The most common causative organism is Chlamydia trachomatis, followed by Neisseria gonorrhoeae, Mycoplasma genitalium, and Mycoplasma hominis. Symptoms of PID include lower abdominal pain, fever, dyspareunia, dysuria, menstrual irregularities, vaginal or cervical discharge, and cervical excitation.

To diagnose PID, a pregnancy test should be done to rule out an ectopic pregnancy, and a high vaginal swab should be taken to screen for Chlamydia and gonorrhoeae. However, these tests may often be negative, so consensus guidelines recommend having a low threshold for treatment due to the potential complications of untreated PID. Management typically involves oral ofloxacin and oral metronidazole or intramuscular ceftriaxone, oral doxycycline, and oral metronidazole. In mild cases of PID, intrauterine contraceptive devices may be left in, but the evidence is limited, and removal of the IUD may be associated with better short-term clinical outcomes according to recent guidelines.

Complications of PID include perihepatitis (Fitz-Hugh Curtis Syndrome), which occurs in around 10% of cases and is characterized by right upper quadrant pain that may be confused with cholecystitis, infertility (with a risk as high as 10-20% after a single episode), chronic pelvic pain, and ectopic pregnancy.

Miscarriage is the loss of a pregnancy before the 20th week. It is a common occurrence, with about 10-20% of pregnancies ending in miscarriage. In most cases, the cause of miscarriage is unknown, but it can be due to genetic abnormalities, hormonal imbalances, or health conditions such as diabetes or thyroid problems.

There are different types of miscarriage, including complete, incomplete, inevitable, and septic. A complete miscarriage is when all fetal tissue has been passed, bleeding has stopped, the uterus is no longer enlarged, and the cervical os is closed. An incomplete miscarriage is when only some fetal parts have been passed, and the cervical os is usually open. An inevitable miscarriage means that a miscarriage is about to occur, with the fetus still possibly alive but the cervical os open and bleeding usually heavier. A septic miscarriage occurs when the contents of the uterus are infected, causing endometritis. Symptoms include offensive vaginal loss, tender uterus, and in cases of pelvic infection, abdominal pain and peritonism.

Types of Miscarriage

Miscarriage is a common complication that can occur during pregnancy. There are different types of miscarriage, each with its own set of symptoms and characteristics. One type is threatened miscarriage, which is painless vaginal bleeding that occurs before 24 weeks, typically at 6-9 weeks. The bleeding is usually less than menstruation, and the cervical os is closed. This type of miscarriage complicates up to 25% of all pregnancies.

Another type is missed (delayed) miscarriage, which is characterized by a gestational sac that contains a dead fetus before 20 weeks without the symptoms of expulsion. The mother may experience light vaginal bleeding or discharge and the disappearance of pregnancy symptoms, but pain is not usually present. The cervical os is closed, and when the gestational sac is larger than 25 mm and no embryonic or fetal part can be seen, it is sometimes referred to as a blighted ovum or anembryonic pregnancy.

Inevitable miscarriage is another type, which is characterized by heavy bleeding with clots and pain. The cervical os is open in this case. Lastly, incomplete miscarriage occurs when not all products of conception have been expelled. This type of miscarriage is characterized by pain and vaginal bleeding, and the cervical os is open. Understanding the different types of miscarriage can help individuals recognize the symptoms and seek appropriate medical attention.

Macrosomia is a significant risk factor for neonatal brachial plexus injuries resulting from shoulder dystocia. Maternal diabetes mellitus, not diabetes insipidus, is the leading cause of macrosomia, which is often associated with a high BMI. While polyhydramnios may result from foetal insulin resistance due to maternal diabetes mellitus, it is not a specific risk factor for brachial plexus injuries as there are many other causes of polyhydramnios. A family history of preeclampsia is not relevant to this condition.

Shoulder dystocia is a complication that can occur during vaginal delivery when the body of the fetus cannot be delivered after the head has already been delivered. This is usually due to the anterior shoulder of the fetus becoming stuck on the mother’s pubic bone. Shoulder dystocia can cause harm to both the mother and the baby.

There are several risk factors that increase the likelihood of shoulder dystocia, including fetal macrosomia (large baby), high maternal body mass index, diabetes mellitus, and prolonged labor.

If shoulder dystocia is identified, it is important to call for senior medical assistance immediately. The McRoberts’ maneuver is often used to help deliver the baby. This involves flexing and abducting the mother’s hips to increase the angle of the pelvis and facilitate delivery. An episiotomy may be performed to provide better access for internal maneuvers, but it will not relieve the bony obstruction. Symphysiotomy and the Zavanelli maneuver are not recommended as they can cause significant harm to the mother. Oxytocin administration is not effective in treating shoulder dystocia.

Complications of shoulder dystocia can include postpartum hemorrhage and perineal tears for the mother, and brachial plexus injury or neonatal death for the baby. It is important to manage shoulder dystocia promptly and effectively to minimize these risks.

During pregnancy, the depth of breathing increases, which is known as tidal volume. This is caused by progesterone relaxing the intercostal muscles and diaphragm, allowing for greater lung inflation during breathing. This is a normal change and is not caused by oestrogen, which typically causes other physical changes during pregnancy such as spider naevi, palmar erythema, and skin pigmentation.

Other physiological changes that occur during pregnancy include increased uterine size, cervical ectropion, increased vaginal discharge, increased plasma volume, anaemia, increased white blood cell count, platelets, ESR, cholesterol, and fibrinogen, as well as decreased albumin, urea, and creatinine. Progesterone-related effects during pregnancy include decreased blood pressure, constipation, ureteral dilation, bladder relaxation, biliary stasis, and increased tidal volume.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

Pregnant women should discontinue the use of ACE inhibitors like ramipril or AIIRA like losartan as they have been linked to negative fetal outcomes. Labetalol is typically the preferred medication for managing hypertension during pregnancy, unless there are medical reasons not to use it.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

Fertilization happens when a sperm reaches an egg that has been released during ovulation. The process begins with the sperm penetrating the outer layer of the egg, called the corona radiata, using enzymes in the plasma membrane of its head. These enzymes bind to receptors on the next inner layer of the egg, called the zona pellucida, triggering the acrosome reaction. This reaction causes the acrosomal hydrolytic enzymes to digest the zona pellucida, creating a pathway to the egg’s plasma membrane. The sperm then enters the egg’s cytoplasm, and the two cells fuse together to form a diploid zygote. The sperm also stimulates the release of calcium ions from the cortical granules of the egg, which inactivate the receptors on the zona pellucida to prevent polyspermy. After fertilization, the zygote undergoes rapid mitotic cell divisions to form an embryo.

The Process of Fertilisation

Fertilisation is the process by which a sperm cell reaches and penetrates an egg cell that has been released during ovulation. The first step involves the sperm penetrating the corona radiata, which is the outer layer of the ovum, using enzymes in the plasma membrane of the sperm’s head. These enzymes bind to the ZP3 receptors on the zona pellucida, which is the next inner layer of the ovum, triggering the acrosome reaction. This reaction involves the acrosomal hydrolytic enzymes digesting the zona pellucida, creating a pathway to the ovum plasma membrane.

Once the sperm enters the ovum cytoplasm, the two cells fuse together, resulting in the formation of a diploid zygote. The sperm also stimulates the release of calcium ions from the cortical granules of the ovum, which inactivate the ZP3 receptors to prevent polyspermy. After fertilisation, rapid mitotic cell divisions occur, resulting in the production of an embryo.

In summary, fertilisation is a complex process that involves the penetration of the ovum by the sperm, the fusion of the two cells, and the subsequent development of the zygote into an embryo.

During pregnancy, progesterone plays a crucial role in causing various changes in the body, including the relaxation of smooth muscles, which leads to a decrease in blood pressure. On the other hand, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) stimulate the release of estrogen and testosterone, which are essential for the menstrual cycle and pregnancy, but do not directly cause any significant changes.

While raised levels of estrogen in the first trimester may cause nausea and other symptoms like spider naevi, palmar erythema, and skin pigmentation, they are not responsible for pregnancy-related cardiovascular changes. Similarly, testosterone typically causes symptoms of hyperandrogenism, such as hirsutism and acne, which are not related to pregnancy but are seen in conditions like polycystic ovary syndrome.

During pregnancy, various physiological changes occur in the body, such as an increase in uterine size, cervical ectropion, increased vaginal discharge, and cardiovascular/haemodynamic changes like increased plasma volume, white cell count, platelets, ESR, cholesterol, and fibrinogen, and decreased albumin, urea, and creatinine. Progesterone-related effects, such as muscle relaxation, can cause decreased blood pressure, constipation, ureteral dilation, bladder relaxation, biliary stasis, and increased tidal volume.

Oestrogen and Progesterone: Their Sources and Functions

Oestrogen and progesterone are two important hormones in the female body. Oestrogen is primarily produced by the ovaries, but can also be produced by the placenta and blood via aromatase. Its functions include promoting the development of genitalia, causing the LH surge, and increasing hepatic synthesis of transport proteins. It also upregulates oestrogen, progesterone, and LH receptors, and is responsible for female fat distribution. On the other hand, progesterone is produced by the corpus luteum, placenta, and adrenal cortex. Its main function is to maintain the endometrium and pregnancy, as well as to thicken cervical mucous and decrease myometrial excitability. It also increases body temperature and is responsible for spiral artery development.

It is important to note that these hormones work together in regulating the menstrual cycle and preparing the body for pregnancy. Oestrogen promotes the proliferation of the endometrium, while progesterone maintains it. Without these hormones, the menstrual cycle and pregnancy would not be possible. Understanding the sources and functions of oestrogen and progesterone is crucial in diagnosing and treating hormonal imbalances and reproductive disorders.

The most common type of ovulatory disorder is normogonadotropic normoestrogenic anovulation, which is often associated with polycystic ovarian syndrome (PCOS). This condition is characterized by normal levels of gonadotropin and estrogen, but low levels of FSH during the follicular phase can lead to anovulation. It is important to perform a thorough evaluation of both male and female factors when investigating infertility. Hypogonadotropic hypogonadal anovulation, which is characterized by low levels of GnRH or pituitary unresponsiveness to GnRH, resulting in low gonadotropins and low estrogen, is seen in conditions such as amenorrhea due to low weight, stress, or Sheehan syndrome. Uterine abnormalities, such as fibroids, may also contribute to infertility, but this is not consistent with the clinical findings in this case. Hypergonadotropic hypoestrogenic anovulation, which is characterized by high levels of gonadotropins but unresponsive ovaries and low estrogen levels, is more commonly seen in conditions such as Turner’s syndrome, primary ovarian failure, or ovary damage.

Understanding Ovulation Induction and Its Categories

Ovulation induction is a common treatment for couples who have difficulty conceiving naturally due to ovulation disorders. The process of ovulation requires a balance of hormones and feedback loops between the hypothalamus, pituitary gland, and ovaries. Anovulation can occur due to alterations in this balance, which can be classified into three categories: hypogonadotropic hypogonadal anovulation, normogonadotropic normoestrogenic anovulation, and hypergonadotropic hypoestrogenic anovulation. The goal of ovulation induction is to induce mono-follicular development and subsequent ovulation, leading to a singleton pregnancy.

There are various forms of ovulation induction, starting with the least invasive and simplest management option first. Exercise and weight loss are typically the first-line treatment for patients with polycystic ovarian syndrome, as ovulation can spontaneously return with even a modest 5% weight loss. Letrozole is now considered the first-line medical therapy for patients with PCOS due to its reduced risk of adverse effects on endometrial and cervical mucous compared to clomiphene citrate. Clomiphene citrate is a selective estrogen receptor modulator that acts primarily at the hypothalamus, blocking the negative feedback effect of estrogens. Gonadotropin therapy tends to be the treatment used mostly for women with hypogonadotropic hypogonadism.

One potential side effect of ovulation induction is ovarian hyperstimulation syndrome (OHSS), which can be life-threatening if not identified and managed promptly. OHSS occurs when ovarian enlargement with multiple cystic spaces form, and an increase in the permeability of capillaries leads to a fluid shift from the intravascular to the extra-vascular space. The severity of OHSS varies, with the risk of severe OHSS occurring in less than 1% of all women undergoing ovarian induction. Management includes fluid and electrolyte replacement, anticoagulation therapy, abdominal ascitic paracentesis, and pregnancy termination to prevent further hormonal imbalances.

Within the broad ligament of the uterus, one can locate the ovaries and the fallopian tubes.

Pelvic Ligaments and their Connections

Pelvic ligaments are structures that connect various organs within the female reproductive system to the pelvic wall. These ligaments play a crucial role in maintaining the position and stability of these organs. There are several types of pelvic ligaments, each with its own unique function and connection.

The broad ligament connects the uterus, fallopian tubes, and ovaries to the pelvic wall, specifically the ovaries. The round ligament connects the uterine fundus to the labia majora, but does not connect to any other structures. The cardinal ligament connects the cervix to the lateral pelvic wall and is responsible for supporting the uterine vessels. The suspensory ligament of the ovaries connects the ovaries to the lateral pelvic wall and supports the ovarian vessels. The ovarian ligament connects the ovaries to the uterus, but does not connect to any other structures. Finally, the uterosacral ligament connects the cervix and posterior vaginal dome to the sacrum, but does not connect to any other structures.

Overall, pelvic ligaments are essential for maintaining the proper position and function of the female reproductive organs. Understanding the connections between these ligaments and the structures they support is crucial for diagnosing and treating any issues that may arise.

Smoking is a protective factor against only one type of cancer, which is endometrial cancer (3), as found by a meta-analysis. However, smoking is a risk factor for all the other types of cancer mentioned.

For bladder cancer (1), it is suggested that the aromatic amines found in cigarettes are a known carcinogen of the bladder, thus contributing to the increased risk of bladder cancer with smoking.

Although smoking is a well-established co-factor for the development of cervical cancer (2), the mechanism by which smoking increases the risk is not known, although there are two theories.

Smoking has been found to cause numerous DNA changes in laryngeal cancer (4), including TP53 gene mutations.

Smoking is also theorized to cause renal cell cancer (5) as cigarette smoke induces oxidative stress and injury in the kidney, and free radicals in cigarettes can cause DNA damage that may lead to the development of cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Symptoms of endometrial cancer include postmenopausal bleeding, which is usually slight and intermittent at first before becoming heavier, and changes in intermenstrual bleeding for premenopausal women. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness of less than 4 mm. Hysteroscopy with endometrial biopsy is also commonly used for diagnosis. Treatment for localized disease typically involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may require postoperative radiotherapy. Progestogen therapy may be used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

The first step in screening for cervical cancer in women aged 25-64 is to test their cervical smear samples for high-risk HPV. If the test is positive, the same sample is then analyzed for abnormal cytology. The recommended frequency of smear tests is every 3 years for women aged 25-49 and every 5 years for women aged 50-64 in the UK screening programme. Therefore, the statements All women are initially screened for abnormal cytology between the ages of 18-64, All women are initially screened for abnormal cytology between the ages of 25-64, and All women are initially screened for abnormal cytology between the ages of 30-64 are incorrect as they either refer to the wrong screening test or age range.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

Primary amenorrhoea occurs when a girl has not started menstruating by the age of 15, despite having normal secondary sexual characteristics like breast development. In girls with no secondary sexual characteristics, primary amenorrhoea is defined as the absence of menstruation by the age of 13. Possible causes of primary amenorrhoea include hypothyroidism and imperforate hymen, but not endometriosis, which typically causes heavy and/or painful periods. While delayed menarche can occur spontaneously before the age of 18, this girl’s symptoms are not within the normal range of variation. Malnutrition or extreme exercise are more likely to cause primary amenorrhoea than obesity-induced amenorrhoea, which typically results in secondary amenorrhoea where periods stop for 6 months or more after menarche has occurred.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

The main cause of menopausal symptoms is low levels of oestrogen, which is why hormone replacement therapy (HRT) aims to alleviate these symptoms by supplementing oestrogen. However, oestrogen can lead to thickening of the endometrium, which increases the risk of neoplasia. To counteract this risk, progesterone is also included in HRT to prevent endometrial thickening and any associated malignancy.

Therefore, any statement suggesting that progesterone is used for symptomatic relief, that oestrogen is protective, or that progesterone and oestrogen work together in a synergistic manner is incorrect.

Symptoms of Menopause

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is characterized by a decrease in the levels of female hormones, particularly oestrogen, which can lead to a range of symptoms. One of the most common symptoms is a change in periods, including changes in the length of menstrual cycles and dysfunctional uterine bleeding.

Around 80% of women experience vasomotor symptoms, which can occur daily and last for up to five years. These symptoms include hot flushes and night sweats. Urogenital changes are also common, affecting around 35% of women. These changes can include vaginal dryness and atrophy, as well as urinary frequency.

In addition to physical symptoms, menopause can also have psychological effects. Approximately 10% of women experience anxiety and depression during this time, as well as short-term memory impairment. It is important to note that menopause can also have longer-term complications, such as an increased risk of osteoporosis and ischaemic heart disease.

Primary amenorrhoea is when a girl has not started menstruating by the age of 15, despite having normal secondary sexual characteristics, or by the age of 13 with no secondary sexual characteristics such as breast development or pubic hair growth. If a girl has not developed any secondary sexual characteristics by the age of 13, this could indicate primary amenorrhoea and should be investigated further with blood tests to rule out any hormonal issues such as Turner’s syndrome. However, if a girl is 8 years old and has not yet developed any secondary sexual characteristics, this is not a concern for primary amenorrhoea but may indicate precocious puberty, which requires treatment. On the other hand, if a 10-year-old girl has not yet developed any secondary sexual characteristics, this is a normal presentation and does not require investigation. Finally, if a 12-year-old girl has normal breast and pubic hair growth, she would need to have three more years of amenorrhoea before it is considered pathological.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.